

# Matteo Bellone

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3634083/matteo-bellone-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110  
papers

3,258  
citations

31  
h-index

54  
g-index

127  
ext. papers

3,836  
ext. citations

7.7  
avg, IF

4.98  
L-index

#	Paper	IF	Citations
110	Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. <i>Cancer Research</i> , <b>2012</b> , 72, 2746-56	10.1	349
109	Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189, 871-6	16.6	184
108	Targeting TNF- $\alpha$ to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. <i>Journal of Immunology</i> , <b>2012</b> , 188, 2687-94	5.3	117
107	Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. <i>Journal of Immunology</i> , <b>2000</b> , 165, 2651-6	5.3	106
106	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 1154-62	6.1	106
105	Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 231	5.3	102
104	Myasthenia gravis: recognition of a human autoantigen at the molecular level. <i>Trends in Immunology</i> , <b>1993</b> , 14, 363-8		96
103	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. <i>Oncolimmunology</i> , <b>2013</b> , 2, e22058	7.2	87
102	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. <i>Nature Communications</i> , <b>2018</b> , 9, 4832	17.4	78
101	Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. <i>Cancer Research</i> , <b>2015</b> , 75, 2095-108	10.1	76
100	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. <i>Journal of Neuroimmunology</i> , <b>2010</b> , 220, 52-63	3.5	75
99	Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 66-75	6.1	68
98	Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. <i>Cancer Research</i> , <b>2004</b> , 64, 7150-5	10.1	63
97	Long non-coding RNAs as novel therapeutic targets in cancer. <i>Pharmacological Research</i> , <b>2016</b> , 110, 131-138		60
96	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , <b>2019</b> , 5, 192-196	5.1	60
95	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. <i>Oncogene</i> , <b>2015</b> , 34, 2094-102	9.2	59
94	Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. <i>Cancer Research</i> , <b>2003</b> , 63, 3688-94	10.1	58

93	Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. <i>Cancer Research</i> , <b>2008</b> , 68, 292-300	10.1	56
92	Modulators of arginine metabolism support cancer immunosurveillance. <i>BMC Immunology</i> , <b>2009</b> , 10, 1	3.7	55
91	Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. <i>European Journal of Immunology</i> , <b>1991</b> , 21, 2303-10	6.1	52
90	iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. <i>PLoS ONE</i> , <b>2010</b> , 5, e8646	3.7	51
89	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 1851-9	6.1	46
88	Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. <i>Cancer Research</i> , <b>2004</b> , 64, 3767-71	10.1	45
87	Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 1105-15	4.2	41
86	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 2691-8	6.1	41
85	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. <i>Blood</i> , <b>2017</b> , 129, 3440-3451	2.2	40
84	Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1265-76	7.5	39
83	Targeting vasculogenesis to prevent progression in multiple myeloma. <i>Leukemia</i> , <b>2016</b> , 30, 1103-15	10.7	37
82	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. <i>Onc Immunology</i> , <b>2013</b> , 2, e24520	7.2	33
81	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. <i>Cell Reports</i> , <b>2018</b> , 22, 3006-3020	10.6	32
80	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. <i>Trends in Immunology</i> , <b>2008</b> , 29, 235-41	14.4	31
79	Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. <i>Scandinavian Journal of Immunology</i> , <b>1995</b> , 42, 215-25	3.4	30
78	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MABs</i> , <b>2013</b> , 5, 34-46	6.6	29
77	Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1109-16		28
76	Apoptosis, cross-presentation, and the fate of the antigen specific immune response. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2000</b> , 5, 307-14	5.4	28

75	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , <b>2021</b> , 374, 216-224	33.3	28
74	Induction of T-cell memory by a dendritic cell vaccine: a computational model. <i>Bioinformatics</i> , <b>2014</b> , 30, 1884-91	7.2	27
73	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2171-2181	12.9	25
72	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. <i>Cancer Letters</i> , <b>1994</b> , 85, 211-6	9.9	25
71	Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1012-23	12.9	24
70	Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN $\gamma$ . <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3859-66	6.1	24
69	Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. <i>Journal of Leukocyte Biology</i> , <b>1999</b> , 66, 247-51	6.5	24
68	Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8 $^+$ cytotoxic T lymphocytes in vitro. <i>Human Gene Therapy</i> , <b>1998</b> , 9, 1335-44	4.8	23
67	Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasis. <i>Cancer Research</i> , <b>2018</b> , 78, 2654-2668	10.1	22
66	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF $\alpha$ Expression and Empower Adoptive Cell Therapy for Solid Tumors. <i>Cancer Research</i> , <b>2017</b> , 77, 658-671	10.1	22
65	Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. <i>Cancer Research</i> , <b>2010</b> , 70, 3505-14	10.1	22
64	Cancer immunotherapy: synthetic and natural peptides in the balance. <i>Trends in Immunology</i> , <b>1999</b> , 20, 457-62		22
63	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?. <i>Neoplasia</i> , <b>2019</b> , 21, 93-105	6.4	22
62	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 453-68	7.4	21
61	Won't you come on in? How to favor lymphocyte infiltration in tumors. <i>OncImmunology</i> , <b>2012</b> , 1, 986-988	8.2	21
60	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 565470	8.4	21
59	ACE polymorphisms and COVID-19-related mortality in Europe. <i>Journal of Molecular Medicine</i> , <b>2020</b> , 98, 1505-1509	5.5	21
58	The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. <i>Journal of Immunology</i> , <b>2005</b> , 174, 3317-25	5.3	20

57	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>OncImmunology</i> , <b>2015</b> , 4, e1008850	7.2	19
56	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , <b>2016</b> , 76, 1781-91	10.1	19
55	A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. <i>OncImmunology</i> , <b>2014</b> , 3, e963406	7.2	19
54	Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses. <i>Journal of Immunology</i> , <b>2006</b> , 177, 2131-7	5.3	19
53	Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. <i>Lupus</i> , <b>2000</b> , 9, 151-4	2.6	19
52	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. <i>Cytokine and Growth Factor Reviews</i> , <b>2017</b> , 36, 17-24	17.9	18
51	Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. <i>Stem Cells Translational Medicine</i> , <b>2013</b> , 2, 678-89	6.9	18
50	Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 799-804	6.1	18
49	Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. <i>Microbiology and Molecular Biology Reviews</i> , <b>2020</b> , 84,	13.2	17
48	Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. <i>Cancer Research</i> , <b>2013</b> , 73, 3545-54	10.1	16
47	Vaccine-instructed intratumoral IFN- $\gamma$ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. <i>Cancer Research</i> , <b>2013</b> , 73, 4641-52	10.1	15
46	Molecular mimicry among human autoantigens. <i>Trends in Immunology</i> , <b>1991</b> , 12, 46-7		15
45	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1786	8.4	14
44	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. <i>Blood</i> , <b>2005</b> , 105, 3596-604	2.2	14
43	Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. <i>Cancer Research</i> , <b>2002</b> , 62, 1116-22	10.1	12
42	Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. <i>Small</i> , <b>2019</b> , 15, e1903462	11	10
41	Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6387-6398	12.9	10
40	Clustering of B and T epitopes within short sequence regions of the nicotinic acetylcholine receptor. <i>Scandinavian Journal of Immunology</i> , <b>1995</b> , 41, 135-40	3.4	9

39	T helper function of CD4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains. <i>Journal of Autoimmunity</i> , <b>1992</b> , 5, 27-46	15.5	9
38	Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1820	8.4	8
37	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR- $\alpha$ <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 365-375	6.1	7
36	Immunotherapy: natural versus synthetic peptides. <i>Trends in Immunology</i> , <b>1998</b> , 19, 98		6
35	Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , <b>2006</b> , 36, 3157-66	6.1	6
34	Immunosuppression via Tenascin-C. <i>Oncoscience</i> , <b>2015</b> , 2, 667-8	0.8	6
33	Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival <b>2019</b> , 7, 201		5
32	Fatty is not that bad: feeding short-chain fatty acids to restrain autoimmunity. <i>Cellular and Molecular Immunology</i> , <b>2017</b> ,	15.4	5
31	Boosting anticancer vaccines: Too much of a good thing?. <i>OncImmunology</i> , <b>2013</b> , 2, e25032	7.2	5
30	Concurrent allorecognition has a limited impact on posttransplant vaccination. <i>Journal of Immunology</i> , <b>2011</b> , 186, 1361-8	5.3	5
29	Use of Synthetic Peptides and High Affinity Protein Ligands for Structural Studies of Central and Peripheral Nicotinic Receptors <b>1989</b> , 291-309		5
28	Characterization of preclinical models of prostate cancer using PET-based molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1245-55	8.8	4
27	Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma. <i>Annals of Hematology</i> , <b>2002</b> , 81, 597-602	3	4
26	Dendritic cell activation kinetics and cancer immunotherapy. <i>Journal of Immunology</i> , <b>2004</b> , 172, 2727-8	5.3	4
25	Autoimmune Disease: Pathogenesis <b>2015</b> , 1-9		3
24	Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. <i>OncImmunology</i> , <b>2013</b> , 2, e25996	7.2	3
23	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. <i>Blood</i> , <b>2013</b> , 122, 680-680	2.2	3
22	[F](2,4)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 760732	5.3	2

21	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. <i>Cytokine and Growth Factor Reviews</i> , <b>2021</b> , 59, 1-8	17.9	2
20	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2019</b> , 173-221	0.3	1
19	Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 2377-8	7.4	1
18	Autoimmune Disease: Pathogenesis <b>2005</b> ,		1
17	Impairment of lymphocyte suppressive system in recent onset insulin-dependent diabetes mellitus. Correlation with blood glucose and serum insulin levels. <i>Acta Diabetologica Latina</i> , <b>1989</b> , 26, 257-63		1
16	Autoimmune Disease: Pathogenesis		1
15	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , <b>2017</b> , 36, 1-3	17.9	0
14	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. <i>Cancer Biology and Medicine</i> , <b>2021</b> ,	5.2	0
13	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in EBTCL1 mice through a CD40L-independent mechanism. <i>Blood Advances</i> , <b>2021</b> , 5, 2817-2828	7.8	0
12	The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 845422	8.4	0
11	"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 131-54	7.4	0
10	Engineered APCs for tumor immunotherapy. <i>Trends in Immunology</i> , <b>1996</b> , 17, 198		
9	Cimetidine Treatment in Hyper-IgM Hypogammaglobulinemia. <i>JAMA - Journal of the American Medical Association</i> , <b>1987</b> , 258, 1892-1892	27.4	
8	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	
7	Development and Validation of [18F](2 S,4 R)-4-Fluoroglutamine in Multiple Myeloma Mouse Models. <i>Blood</i> , <b>2021</b> , 138, 2674-2674	2.2	
6	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	
5	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. <i>Blood</i> , <b>2019</b> , 134, 683-683	2.2	
4	[18f]-(2S,4R)-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 5542-5542	2.2	

- 3 Autoimmunity Against the Nicotinic Acetylcholine Receptor and the Presynaptic Calcium Channel at the Neuromuscular Junction. *E&M Endocrinology and Metabolism*, **1994**, 151-189
- 2 Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. *Blood*, **2014**, 124, 4719-4719 2.2
- 1 Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. *Blood*, **2014**, 124, 5678-5678 2.2